Talphera Reports Third Quarter 2026 Financial Results and Provides Business Update

TALPHERA, INC. (TLPH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Talphera Reports Third Quarter 2026 Financial Results and Provides Business Update Briefing document submitted to FDA for a Sprint Meeting requesting a close of the NEPHRO CRRT study enrollment based on number of patients enrolled as of December 31, 2026 Pivotal NEPH

Event · Earnings
Original reporting
Published Nov 12, 2026, 9:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 9:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$TLPH
Neutral
high confidence
Mentioned
$TLPH
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$TLPHNeutralMed
01

Why it matters

The Q3 results and updated market research provide the first public view of the company's financial health and commercial potential, offering traders fresh data to reassess valuation.

02

Market read

First‑report 8‑K disclosure of quarterly results and updated sales estimate; modest trading relevance for biotech investors.

03

What to watch

Regulatory feedback on the early‑close enrollment request and competitive anticoagulant pipelines could influence future valuation.

Relevance 7/10Novelty 7/10Timing: post‑market today after earnings release

Background

Talphera is a specialty pharmaceutical company developing nafamostat (Niyad) for continuous renal replacement therapy.

Company-level read

Ticker impact

$TLPHNeutralHigh confidence
Context

Talphera filed an 8‑K reporting Q3 2026 results, updated peak‑sales estimate for nafamostat to >$200 M and provided enrollment status for its NEPHRO CRRT study.

Expected impact

potential modest upside as sales estimate rises, offset by enrollment slowdown risk

Evidence & confidence

New financial numbers and a higher sales target are fresh information; investors may reprice the stock, yet the enrollment slowdown introduces downside pressure.

Market effects

Highlights continued interest in renal‑replacement‑therapy anticoagulants, potentially benefiting peer biotech firms in the CRRT space.

No immediate regional effect beyond the U.S. biotech sector.

Limited to niche specialty‑pharma investors; not a broad market driver.

Counterpoint

The enrollment slowdown could signal deeper trial challenges, suggesting the stock may face pressure despite the higher sales estimate.

Key entities

  • Talphera, Inc.

    Specialty pharma developing nafamostat for CRRT.

  • Vince Angotti

    CEO of Talphera, quoted on trial progress and sales outlook.

Related articles

$TLPHMed

Talphera (TLPH) Q3 2026 Earnings Call Transcript

Talphera (TLPH) reported Q3 2026 earnings, seeking FDA approval to conclude Niyad enrollment early due to 80% statistical power. They increased peak U.S. sales estimate to over $200M. Cash balance was $14.2M, with $16M in potential financing. Operating expenses rose to $3.8M from $3.3M YoY. Enrollment challenges were discussed, with no clear cause identified.

$TLPHMed

What Talphera (TLPH) Said on Its Q3 Earnings Call

Talphera (TLPH) discussed Q3 earnings, highlighting FDA submission details, increased peak-sales estimates, and cash position. The company expects $14.2M in cash and $16M in conditional financing to support operations through 2027. Expenses rose to $3.8M due to Niyad development and pre-launch activities. Talphera plans an investor event in Q1 2027 to discuss opportunities.

$TLPHMedAI 8/10

Talphera at H.C. Wainwright conference: nafamostat path gains traction

Talphera (TLPH) updated investors on its nafamostat mesylate clinical trial at the H.C. Wainwright conference. The NEPHRO study is 75% enrolled, with topline data expected in early 2025 and a potential U.S. launch in late 2025. The FDA reduced the study size to 70 patients, maintaining 90% statistical power. New guidelines recommend nafamostat, and the company sees a larger U.S. market opportunity. The stock has gained 56% over six months, with analysts setting price targets between $3 and $3.50

$TLPHMed

Talphera Announces Second Quarter 2026 Financial Results and Provides Corporate Update

TALPHERA, INC. (TLPH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Talphera Announces Second Quarter 2026 Financial Results and Provides Corporate Update NEPHRO CRRT clinical study of nafamostat is 75% enrolled; expected to be complete this year Draft 2026 KDIGO guidelines added nafamostat as an acceptable CRRT anticoagulant, a posi